Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
Clinical trial NCT04467840 · COMPLETED
Trial details
- NCT number
- NCT04467840
- Sponsor
- RedHill Biopharma Limited
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-21
- Primary completion
- 2021-07-18
- Enrollment
- 475
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.